IL-15Rα+ TAMs have been reported to limit the recruitment of CD8+ T lymphocytes by reducing CX3CL1 expression in breast cancer cells and releasing the IL-15/IL-15Rα complex (IL-15Rc) 40. This evidence concerns the gene CD8A and breast carcinoma.